HPV type | Anal | Penile | Penile/Anal | |||
N=252 | N=250 | N=253 | ||||
n | % | n | % | n | % | |
A. HPV DNA positivity, n (%) | ||||||
Any type | 74 | 29.4 | 29 | 11.6 | 87 | 34.4 |
High-risk types* | ||||||
Any high-risk types | 52 | 20.6 | 17 | 6.8 | 62 | 24.5 |
16 | 8 | 3.2 | 0 | 0 | 8 | 3.2 |
18 | 2 | 0.8 | 1 | 0.4 | 2 | 0.8 |
31 | 1 | 0.4 | 0 | 0 | 1 | 0.4 |
33 | 7 | 2.8 | 2 | 0.8 | 8 | 3.2 |
35 | 3 | 1.2 | 0 | 0 | 3 | 1.2 |
39 | 6 | 2.4 | 2 | 0.8 | 8 | 3.2 |
45 | 3 | 1.2 | 0 | 0 | 3 | 1.2 |
51 | 2 | 0.8 | 1 | 0.4 | 3 | 1.2 |
52 | 11 | 4.4 | 3 | 1.2 | 13 | 5.1 |
53 | 1 | 0.4 | 0 | 0 | 1 | 0.4 |
56 | 8 | 3.2 | 1 | 0.4 | 9 | 3.6 |
58 | 6 | 2.4 | 4 | 1.6 | 8 | 3.2 |
59 | 5 | 2 | 2 | 0.8 | 6 | 2.4 |
66 | 7 | 2.8 | 1 | 0.4 | 7 | 2.8 |
67 | 1 | 0.4 | 0 | 0 | 1 | 0.4 |
68 | 7 | 2.8 | 3 | 1.2 | 10 | 4 |
73 (MM9) | 1 | 0.4 | 1 | 0.4 | 2 | 0.8 |
Age at recruitment (years) | ||||||
20–24 | 16 | 21.1 | 7 | 9.2 | 21 | 27.6 |
25–29 | 16 | 18.6 | 3 | 3.5 | 17 | 19.8 |
30–34 | 11 | 19 | 5 | 8.6 | 14 | 24.1 |
35–44 | 8 | 28.9 | 2 | 7.1 | 9 | 32.1 |
45+ (max 50) | 1 | 20 | 0 | 0 | 1 | 20 |
Low-risk types† | ||||||
Any low-risk types | 38 | 15.1 | 15 | 6 | 47 | 18.6 |
6 | 32 | 12.7 | 12 | 4.8 | 38 | 15 |
11 | 8 | 3.2 | 1 | 0.4 | 9 | 3.6 |
40 | 1 | 0.4 | 1 | 0.4 | 2 | 0.8 |
42 | 7 | 2.8 | 1 | 0.4 | 8 | 3.2 |
54 | 0 | 0 | 1 | 0.4 | 1 | 0.4 |
62 | 2 | 0.8 | 0 | 0 | 2 | 0.8 |
84 (MM8) | 0 | 0 | 1 | 0.4 | 1 | 0.4 |
Age at recruitment (years) | ||||||
20–24 | 15 | 19.7 | 6 | 7.9 | 18 | 23.7 |
25–29 | 14 | 16.3 | 4 | 4.7 | 16 | 18.6 |
30–34 | 3 | 5.2 | 2 | 3.5 | 5 | 8.6 |
35–44 | 5 | 17.8 | 3 | 10.7 | 7 | 25 |
45+ (max 50) | 1 | 20 | 0 | 0 | 1 | 20 |
Vaccine-preventable types | ||||||
6/11/16/18/31/33/45/52/58 | 57 | 22.6 | 20 | 8 | 63 | 24.9 |
6/11/16/18 | 40 | 15.9 | 12 | 4.8 | 45 | 17.8 |
6/11 | 33 | 13.1 | 12 | 4.8 | 39 | 15.4 |
16/18 | 10 | 4 | 1 | 0.4 | 10 | 4 |
B. Detection of m ultiple HPV types | ||||||
Any type | ||||||
Range | ||||||
0 | 178 | 70.6 | 221 | 88.4 | 166 | 65.6 |
1 | 37 | 14.7 | 23 | 9.2 | 43 | 17 |
2 | 23 | 9.1 | 3 | 1.2 | 26 | 10.3 |
3 | 11 | 4.4 | 3 | 1.2 | 14 | 5.5 |
4+ | 3 | 1.2 | 0 | 0 | 4 | 1.6 |
4-valent vaccine types | ||||||
Range | ||||||
0 | 212 | 84.1 | 238 | 95.2 | 208 | 82.2 |
1 | 30 | 11.9 | 10 | 4 | 33 | 13 |
2 | 10 | 4 | 2 | 0.8 | 12 | 4.7 |
9-valent vaccine types | ||||||
Range | ||||||
0 | 195 | 77.4 | 230 | 92 | 190 | 75.1 |
1 | 39 | 15.5 | 17 | 6.8 | 39 | 15.4 |
2 | 15 | 6 | 3 | 1.2 | 21 | 8.3 |
3 | 3 | 1.2 | 0 | 0 | 3 | 1.2 |
*High-risk types included type 26, 69, 70 and 82 (MM4), but no one in this sample was detected as such.
†Low-risk types included type 55, 61, 64, 71 (CP8061), 72, 81 (CP8304), 83 (MM7), 82V and 89 but no one in this sample was detected as such.
HPV, human papillomavirus.